Time to Tmax between 1-3 h post dose in fasted state;
following 50 mg oral dose, mean Cmax (total circulating radioactivity, unchanged midostaurin, and metabolites CGP52421 and CGP62221)=2160 ng/mL, 1240 ng/mL, 328 ng/mL and 562 ng/mL, respectively;
mean AUC (0-infinity) (total circulating radioactivity, unchanged midostaurin, and metabolites CGP52421 and CGP62221) =165 x 103 ng Eq*h/mL, 15.7 x 103 ng*h/mL, 146 x 103 ng*h/mL, and 27.1 x 103 ng*h/mL, respectively;
high oral absorption rate following 50 mg dose (190);
rat and dog: bioavailability low to moderate (9.3-48.5%); human oral bioavailability low to moderate (190);
Vd =95.2L (parent drug and metabolites distributed in plasma)